Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

25.31
+2.3510.24%
Post-market: 25.400.0900+0.36%18:20 EDT
Volume:1.88M
Turnover:46.89M
Market Cap:2.84B
PE:-16.47
High:25.85
Open:23.35
Low:23.23
Close:22.96
52wk High:27.29
52wk Low:14.06
Shares:112.27M
Float Shares:54.90M
Volume Ratio:3.00
T/O Rate:3.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5367
EPS(LYR):-2.5604
ROE:-28.43%
ROA:-17.12%
PB:3.65
PE(LYR):-9.89

Loading ...

Company Profile

Company Name:
NEWAMSTERDAM PHARMA CO NV
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
77
Office Location:
Gooimeer 2-35,Naarden,Noord-Holland,Netherlands
Zip Code:
1411 DC
Fax:
- -
Introduction:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Directors

Name
Position
Michael Davidson
Chief Executive Officer, Director
Janneke van der Kamp
Temporary Director
John Kastelein
Chief Scientific Officer and Director
John W. Smither
Temporary Director
Juliette Audet
Vice Chairperson, Director
Sander Slootweg
Chairperson, Director
James N. Topper
Director
Louis Lange
Director
Nicholas Downing
Director

Shareholders

Name
Position
Michael Davidson
Chief Executive Officer, Director
Douglas Kling
Chief Operating Officer
Louise Kooij
Interim Chief Financial Officer
John Kastelein
Chief Scientific Officer and Director
Marc Ditmarsch
Chief Development Officer